Metformin suppresses CRC growth by inducing apoptosis via ADORA1

Front Biosci (Landmark Ed). 2017 Jan 1;22(2):248-257. doi: 10.2741/4484.

Abstract

Accumulating evidence suggests that the anti-diabetic drug, metformin, exerts anti-proliferative effects in many types of cancers. However, the function and mechanisms of metformin in human colorectal cancer (CRC) remain unknown. Here, we show that metformin induces growth inhibition and apoptosis through activating AMPK-mTOR pathway in human colorectal cancer cells. Notably, metformin treatment significantly up-regulated adenosine A1 receptor (ADORA1) expression in human colorectal cancer cells, while suppression of ADORA1 activity by its specific inhibitor rescued the growth inhibition induced by metformin. Moreover, ADORA1-mediated growth inhibition and apoptosis induced by metformin is AMPK-mTOR pathway dependent in human colorectal cancer cells. Taken together, these results indicate that metformin suppresses human colorectal cancer growth by inducing apoptosis via ADORA1, which provide evidence the anti-neoplastic effects of metformin in the treatment of human colorectal cancer.

MeSH terms

  • Adenosine A1 Receptor Agonists / pharmacology
  • Adenosine A1 Receptor Antagonists / pharmacology
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / metabolism
  • Colorectal Neoplasms / pathology
  • HCT116 Cells
  • Humans
  • Metformin / pharmacology*
  • Receptor, Adenosine A1 / genetics
  • Receptor, Adenosine A1 / metabolism*
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / metabolism
  • Up-Regulation / drug effects

Substances

  • Adenosine A1 Receptor Agonists
  • Adenosine A1 Receptor Antagonists
  • Antineoplastic Agents
  • Receptor, Adenosine A1
  • Metformin
  • MTOR protein, human
  • TOR Serine-Threonine Kinases